B-cell maturation target (BCMA) has recently emerged out as potential target for the development of novel immunotherapies in multiple myeloma.
Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market & Clinical Trials Insight 2026 Report Analysis and Data Highlights:
- Research Methodology
- Global & Regional Market Analysis
- Global BCMA Targeted Drugs Market Opportunity Assessment: > USD 4 Billion
- Market and Drug Sales Insight 2020 Till 2026
- Approved Drug In Market: 2 Drugs
- Approved BCMA Targeted Drugs Patent, Price and Sales insight 2020 Till 2026
- Future Market Assessment By Indication Till 2026
- Ongoing Clinical Trials Assessment by Status, Phase & Region
- Key Market Dynamics
- Competitor Landscape
Download Report:
B-cell maturation target (BCMA) has recently emerged out as potential target for the development of novel immunotherapies in multiple myeloma. Since its identification, researchers have adopted several different approaches to develop novel drugs which can target BCMA as an alternate for the management of cancer. In 2020, Blenrep (belantamab mafodotin) developed by GlaxoSmithKline was the first BCMA targeted drug which was approved by US FDA for the management of multiple myeloma. Blenrep is antibody drug conjugate, in which the the antibody is coupled to the microtubule inhibitor monomethylauristatin F (MMAF) through a protease-resistant maleimidocaproyl linker.
Abecma is a B-cell maturation antigen (BCMA)-directed genetically modified autologous chimeric antigen receptor (CAR) T-cell therapy. The drug was developed by Bistol Myers Squibb and was granted approval in 2021 for the management of multiple myeloma. Currently, only two BCMA targeted therapies have gained entry into the market which has shown encouraging response in the market. This has also surged the further research and development activities in this sector. For instance, Ciltacabtagene Autoleucel (Cilta-cel) developed by Janssen Pharmaceuticals is investigational BCMA CAR T-cell therapy which is expected to enter the market by 2022, which will further boost the growth of market in forthcoming years. In addition to this, Poseida Therapeutics has developed P-BCMA-101, a non-viral transposon-based autologous CAR-T, which was well-tolerated and demonstrated strong anti-tumor activity in advanced multiple myeloma patients.
Apart from antibody drug conjugates and CAR T-cell therapies, the pipeline for BCMA targeted therapy also consists of bispecific antibodies. Bispecific antibodies are novel immunotherapeutic approach which is designed to bind antigens on malignant cells and cytotoxic immune effector cells. Several BCMA targeting bispecific antibodies have been developed using AMG701, AMG420, Teclistamab, REGN5458, PF-06863135, are present majorly in phase-I/II clinical trials and are expected to enter the market during forthcoming years.
With an aim of improving the market penetrability and commercialization of BCMA targeted drugs, the leading pharmaceutical companies are expected to collaborate with CROs and regional pharmaceutical companies of developing companies, which will increase the market size of this novel segment in regions such as Asia-Pacific, Middle-East and Latin America. For instance, Sprinkwork Therapeutics has entered into clinical trial collaboration with AbbVie, to evaluate nirogacestat, SpringWorks’ investigational gamma secretase inhibitor, in combination with ABBV-383; AbbVie’s investigational CD3 bispecific antibody directed against B-cell maturation agent (BCMA), in patients with relapsed or refractory multiple myeloma.
The global BCMA targeted therapy market is expected to surpass US$ 4 Billion by 2026. Rising awareness about the availability of innovative and easy intake drugs for cancer treatment is providing a stimulus to BCMA targeted therapies. Furthermore, high prevalence of cancer, coupled with growing demand for effective drugs are the prominent drives for the growth of market. Additionally, rapid technological advancements in healthcare sector and surging demand for outsourcing clinical trials is also projected to accelerate the market growth during the forecast period. Currently, more than 100 clinical trials are ongoing which are evaluating the role of BCMA targeted therapies in multiple myeloma. Apart from this, researchers are also evaluating the role of BCMA targeted therapies in other cancers including lymphoma and leukemia, which will further boost the growth of market during forecast period.
The global BCMA targeted drug report involves in depth analysis of the various parameters related to this segment along with the analysis of current as well as future market opportunity. The report also analyzes the wide range of applications of this class in cancer management along with the clinical trends, market drivers, and possible challenges related to BCMA targeted drugs market. Further, multiple parameters are considered to forecast and analyze the global, regional and indication based market size for BCMA targeted drugs.
For More Information Related To Report Contact:
Neeraj Chawla
Research Head
Kuick Research
+919810410366